Quarterly report · Q1
4483.TEDINET S100RPCP
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.7bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥5.8bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥2.5bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥2.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.0bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥765m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.0bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥759m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥97.5bn | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥63.3bn | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥31.7bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥65.8bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.4bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥65.9bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.4bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥23.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.4bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥273m | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥909m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥32.42 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥13.55 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.07 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥12.73 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.5% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.7% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥76m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥76m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥151m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥969m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥919m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥50m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥87m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥25m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥448m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥6.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥6.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥76m |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥90m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥910m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥869m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥41m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥47m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥17m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥439m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥58m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 632
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividends ss IFRS | CurrentYTDDuration | -754000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | -3000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | 3000000 | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | － | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Transfer to retained earnings ss IFRS | CurrentYTDDuration | － | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | -4000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | -751000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | -726000000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_NonControllingInterestsIFRSMember | － | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration | -726000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_OtherComponentsOfEquityIFRSMember | 26000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_RetainedEarningsIFRSMember | 14597000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 65856000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_NonControllingInterestsIFRSMember | -14000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 65841000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 1120000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 2552000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 444000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 551000000 | JPY |
| Other income ope cf IFRS | Prior1YTDDuration | -19000000 | JPY |
| Other income ope cf IFRS | CurrentYTDDuration | -1458000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 438000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 1509000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -25000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | 6000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -181000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -701000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | 342000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 177000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 2119000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 2636000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 0 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 0 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -13000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -5000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -1016000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -1191000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 1089000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 1439000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -180000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -62000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -318000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -263000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YTDDuration | -150000000 | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -2729000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -1450000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | CurrentYTDDuration | 273000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |